Skip to main content
TipRanks
Go Ultimate75% OFF
FoRx Therapeutics logo

FoRx Therapeutics: Valuation, Funding & Investors

Basel, Basel 4056, CHhttps://www.forxtx.com/Precision Medicine

FoRx Therapeutics is a privately held clinical-stage biotechnology company developing precision therapeutics that target the DNA Damage Response (DDR) in treatment-resistant cancers. The company’s lead product candidate, FORX-428, is an oral small-molecule PARG inhibitor in Phase 1 development for advanced solid tumors, aimed at treating cancers resistant to PARP inhibitors.

Leadership & Board

Current Number of Employees
34
Current LinkedIn Followers
7,575

Latest Estimated Valuation

Total Amount Raised
$50M
Total Funding Rounds
1
Latest Funding Amount
$50M
Latest Funding Round
Series A

Employee Trend

FoRx Therapeutics had 34 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.

34Latest Employee Count
0(0.00%)Week-Over-Week Change
010203040Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Social Trend

FoRx Therapeutics had 7,575 followers as of November 16, 2026. The number of followers increased by 28 (0.37%) week-over-week.

7,575Latest Followers Count
28(0.37%)Week-Over-Week Change
02,0004,0006,0008,000Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Dec 18, 2025Series A$50.00M―

Investors

Investor NameFunding Round
M VenturesSeries A
EQT Life SciencesSeries A
Novartis Venture FundSeries A
Pfizer VenturesSeries A

Similar Companies

A snapshot of private companies similar to FoRx Therapeutics, helping you discover and navigate related company profiles.

Related News and Analysis